JP2005535581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535581A5 JP2005535581A5 JP2004500839A JP2004500839A JP2005535581A5 JP 2005535581 A5 JP2005535581 A5 JP 2005535581A5 JP 2004500839 A JP2004500839 A JP 2004500839A JP 2004500839 A JP2004500839 A JP 2004500839A JP 2005535581 A5 JP2005535581 A5 JP 2005535581A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- pharmaceutical composition
- composition according
- pulmonary
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 6
- 230000000704 physical effect Effects 0.000 claims 5
- 208000019693 Lung disease Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 3
- 230000035784 germination Effects 0.000 claims 3
- 210000004877 mucosa Anatomy 0.000 claims 3
- 210000003097 mucus Anatomy 0.000 claims 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 claims 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 108010007979 Glycocholic Acid Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- ZBNRGEMZNWHCGA-PDKVEDEMSA-N [(2r)-2-[(2r,3r,4s)-3,4-bis[[(z)-octadec-9-enoyl]oxy]oxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC ZBNRGEMZNWHCGA-PDKVEDEMSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- -1 sorbitan fatty acid ester Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 claims 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims 1
- 229960004224 tyloxapol Drugs 0.000 claims 1
- 229920001664 tyloxapol Polymers 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37732702P | 2002-05-02 | 2002-05-02 | |
| PCT/US2003/013707 WO2003092654A1 (en) | 2002-05-02 | 2003-05-01 | Formulations limiting spread of pulmonary infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011116395A Division JP2011157405A (ja) | 2002-05-02 | 2011-05-24 | 肺感染の拡大を制限する処方物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535581A JP2005535581A (ja) | 2005-11-24 |
| JP2005535581A5 true JP2005535581A5 (https=) | 2006-06-22 |
Family
ID=29401482
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500839A Pending JP2005535581A (ja) | 2002-05-02 | 2003-05-01 | 肺感染の拡大を制限する処方物 |
| JP2011116395A Pending JP2011157405A (ja) | 2002-05-02 | 2011-05-24 | 肺感染の拡大を制限する処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011116395A Pending JP2011157405A (ja) | 2002-05-02 | 2011-05-24 | 肺感染の拡大を制限する処方物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8858917B2 (https=) |
| EP (1) | EP1531795A4 (https=) |
| JP (2) | JP2005535581A (https=) |
| AU (1) | AU2003243191B2 (https=) |
| CA (1) | CA2483917C (https=) |
| WO (1) | WO2003092654A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003092654A1 (en) | 2002-05-02 | 2003-11-13 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
| GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US20050207983A1 (en) * | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| AU2006247077A1 (en) | 2005-05-18 | 2006-11-23 | Pulmatrix Inc. | Formulations for alteration of biophysical properties of mucosal lining |
| US20100172845A1 (en) * | 2007-05-29 | 2010-07-08 | Board Of Regents Of The University Of Texas System | Compositions and methods for treating mycobacterial infections |
| CN102448438A (zh) * | 2009-03-26 | 2012-05-09 | 普马特里克斯公司 | 抗流行性感冒调配物及方法 |
| WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| AU2011325966B2 (en) * | 2010-11-12 | 2016-09-29 | Oncour Pharma, Inc. | Modified immune-modulating particles |
| US9693990B2 (en) | 2011-10-14 | 2017-07-04 | The Trustees Of The Stevens Institute Of Technology | Use of rhodamine dyes to reduce alveolar surface tension |
| US9504796B2 (en) * | 2011-10-14 | 2016-11-29 | The Trustees Of The Stevens Institute Of Technology | Reducing ventilator-induced lung injury |
| CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| JP5478693B2 (ja) * | 2012-03-23 | 2014-04-23 | 太平洋セメント株式会社 | 二次電池用正極活物質及びその製造方法 |
| CN110064049B (zh) | 2012-06-21 | 2024-02-09 | 西北大学 | 肽缀合粒子 |
| EP3494966B1 (en) | 2013-03-13 | 2024-04-03 | onCOUR Pharma, Inc. | Immune-modifying particles for the treatment of inflammation |
| KR20160042079A (ko) | 2013-08-13 | 2016-04-18 | 노쓰웨스턴유니버시티 | 펩티드-접합된 입자 |
| US10391151B2 (en) | 2015-06-29 | 2019-08-27 | The Trustees Of The Stevens Institute Of Technology | Dilute surfactant or isolated surfactant protein solution for the reduction of surface tension in the lung |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US37053A (en) | 1862-12-02 | Improved me at-cutter | ||
| DE3229179C2 (de) * | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
| US4899914A (en) | 1988-11-04 | 1990-02-13 | Ciba-Geigy Corporation | Method for producing a sterile preservative-free aerosol saline solution |
| US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| US5175152A (en) | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
| US5211944A (en) | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
| US5466680A (en) * | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| JP3961029B2 (ja) * | 1992-06-24 | 2007-08-15 | 博 木戸 | インフルエンザウィルス感染防止剤 |
| US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
| US5514665A (en) * | 1993-12-30 | 1996-05-07 | University Of British Columbia | Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans |
| AUPM411494A0 (en) * | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
| US5633003A (en) * | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
| CA2145948A1 (en) * | 1994-04-06 | 1995-10-07 | Wendell A. Ehrhart | Floor covering having a (meth)acrylated, highly ethoxylated, aromatic polyester wear layer |
| US5863563A (en) | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
| DK0812195T3 (da) * | 1995-02-28 | 2003-03-03 | Aventis Pharma Inc | Farmaceutisk sammensætning til piperidinoalkanolforbindelser |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| WO1997029738A1 (en) * | 1996-02-16 | 1997-08-21 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating eustachian tube dysfunction by inhalation |
| GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| DE19653969A1 (de) | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| CA2277801C (en) * | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6339075B1 (en) * | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
| US5883084A (en) | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
| AU2001264817A1 (en) * | 2000-05-23 | 2001-12-17 | Exhale Therapeutics, Inc. | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| US6669959B1 (en) * | 2000-07-18 | 2003-12-30 | Aeropharm Technology Incorporated | Modulated release particles for lung delivery |
| WO2002009574A2 (en) | 2000-08-01 | 2002-02-07 | Shofner Engineering Associates, Inc. | Generation, delivery, measurement and control of aerosol boli for diagnostics and treatment of the respiratory tract |
| KR100743404B1 (ko) | 2000-12-21 | 2007-07-30 | 넥타르 테라퓨틱스 | 폴리엔 항균제의 폐 전달 |
| WO2003092654A1 (en) | 2002-05-02 | 2003-11-13 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
| WO2003094900A1 (en) | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| US20050207983A1 (en) * | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| WO2005094869A1 (en) * | 2004-03-30 | 2005-10-13 | Malcolm King | Compositions and methods for improved mucus function |
| US8627821B2 (en) * | 2005-01-10 | 2014-01-14 | Pulmatrix, Inc. | Method and device for decreasing contamination |
| US9708895B2 (en) | 2013-05-07 | 2017-07-18 | Halliburton Energy Services, Inc. | Intrawell fluid injection system and method |
-
2003
- 2003-05-01 WO PCT/US2003/013707 patent/WO2003092654A1/en not_active Ceased
- 2003-05-01 CA CA2483917A patent/CA2483917C/en not_active Expired - Fee Related
- 2003-05-01 AU AU2003243191A patent/AU2003243191B2/en not_active Ceased
- 2003-05-01 JP JP2004500839A patent/JP2005535581A/ja active Pending
- 2003-05-01 EP EP03747647A patent/EP1531795A4/en not_active Withdrawn
-
2009
- 2009-01-09 US US12/351,328 patent/US8858917B2/en not_active Expired - Fee Related
-
2011
- 2011-05-24 JP JP2011116395A patent/JP2011157405A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535581A5 (https=) | ||
| AU2009225363B2 (en) | Formulations for decreasing infectivity of pulmonary disease | |
| US8858917B2 (en) | Methods for limiting spread of pulmonary infections | |
| CN102448440A (zh) | 治疗呼吸道感染的医药调配物及方法 | |
| CZ300758B6 (cs) | Práškovitý prípravek obsahující perforované mikrostruktury | |
| AU2021244864B2 (en) | 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury | |
| JP2007507423A (ja) | 病原体感染の危険を低減する方法 | |
| KR20080018872A (ko) | 점막 내층의 생물물리학적 특성의 변화를 위한 제제 | |
| US20060002995A1 (en) | Pharmaceutical porous particles | |
| AU2003287132B2 (en) | Pharmaceutical porous particles | |
| CA3199912A1 (en) | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection | |
| US20050220720A1 (en) | Formulations limiting spread of pulmonary infections | |
| JP2023523035A (ja) | キニーネ及び先天性免疫応答を生じさせるためのその使用 | |
| US20210046108A1 (en) | Dissolved c60 and method of producing dissolved c60 | |
| JP2023528883A (ja) | 呼吸器系傷害改善用医薬組成物及び呼吸器系傷害改善用医薬組成物の製造のための用途 | |
| TW202602487A (zh) | 呼吸系統疾病的治療與預防 | |
| HK40102228A (zh) | 用於sars-cov-2感染的後遗症的预防和治疗的鲁米诺 | |
| Sievers et al. | Micronization of measles vaccine and siRNA by CAN-BD for aerosol delivery by air expansion of powders with a PuffHaler™ | |
| HK1165990A (en) | Formulations for alteration of biophysical properties of mucosal lining | |
| HK1121064A (en) | Formulations for alteration of biophysical properties of mucosal lining | |
| AU2012258353A1 (en) | Formulations for alteration of biophysical properties of mucosal lining | |
| HK1167595A (en) | Formulations for alteration of biophysical properties of mucosal lining | |
| MX2007014468A (en) | Formulations for alteration of biophysical properties of mucosal lining |